EGFR and non-small cell lung carcinoma: <h4>Background</h4>Advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations has been successfully treated with tyrosine kinase inhibitors (TKIs).